The Impact of Antibiotic Prophylaxis on Incidence of Post-bronchoscopy Fever and Change of Serum Cytokines
Primary Purpose
Fever, Pneumonia
Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
oral amoxicillin/clavulanate 1g (875/125mg)
control
Sponsored by
About this trial
This is an interventional prevention trial for Fever focused on measuring bronchoscopy, post-bronchoscopy fever, pneumonia, cytokines, amoxicillin/clavulanate, prophylaxis
Eligibility Criteria
Inclusion Criteria:
- adult patients (aged 18 years or older) who underwent FB
Exclusion Criteria:
- concurrent treatment with antibiotics or systemic corticosteroid
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
No Intervention
Active Comparator
Arm Label
control
Amoxicillin/clavulanate
Arm Description
control without intervention
Outcomes
Primary Outcome Measures
The incidence of fever
time frame for body temperature 24hr before and after bronchoscopy every 4hrs
Secondary Outcome Measures
change of serum cytokines level
Time frame for cytokine measurement 24hr before brochoscopy - 1hr after bronchosocpy - 24hr after brochoscopy
Full Information
NCT ID
NCT01089218
First Posted
March 14, 2010
Last Updated
July 19, 2011
Sponsor
Seoul National University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT01089218
Brief Title
The Impact of Antibiotic Prophylaxis on Incidence of Post-bronchoscopy Fever and Change of Serum Cytokines
Official Title
The Impact of Antibiotic Prophylaxis on Incidence of Post-bronchoscopy Fever and Change of Serum Cytokines
Study Type
Interventional
2. Study Status
Record Verification Date
July 2011
Overall Recruitment Status
Completed
Study Start Date
April 2008 (undefined)
Primary Completion Date
January 2009 (Actual)
Study Completion Date
February 2010 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Seoul National University Hospital
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Fever can develop after fiberoptic bronchoscopy (FB) in about 2.5 - 16 % of adult patients. We evaluated the impact of oral amoxicillin/clavulanate (AC) on incidence of postbronchoscopic fever and pneumonia.
Detailed Description
For the population being undergone with bronchoscopy, the clinical signs and procedural measures for complication of bronchoscopy and cytokines will be checked.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fever, Pneumonia
Keywords
bronchoscopy, post-bronchoscopy fever, pneumonia, cytokines, amoxicillin/clavulanate, prophylaxis
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Investigator
Allocation
Randomized
Enrollment
241 (Actual)
8. Arms, Groups, and Interventions
Arm Title
control
Arm Type
No Intervention
Arm Description
control without intervention
Arm Title
Amoxicillin/clavulanate
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
oral amoxicillin/clavulanate 1g (875/125mg)
Other Intervention Name(s)
prophylaxis group
Intervention Description
oral amoxicillin/clavulanate 1g (875/125mg) on the day of the procedure 30 minutes prior to the FB
Intervention Type
Drug
Intervention Name(s)
control
Intervention Description
no intervention with the same procedure of FB
Primary Outcome Measure Information:
Title
The incidence of fever
Description
time frame for body temperature 24hr before and after bronchoscopy every 4hrs
Time Frame
24 hr after bronchoscopy
Secondary Outcome Measure Information:
Title
change of serum cytokines level
Description
Time frame for cytokine measurement 24hr before brochoscopy - 1hr after bronchosocpy - 24hr after brochoscopy
Time Frame
before bronchoscopy and 24hr after bronchoscopy
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
adult patients (aged 18 years or older) who underwent FB
Exclusion Criteria:
concurrent treatment with antibiotics or systemic corticosteroid
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Deog Kyeom Kim, MD.
Organizational Affiliation
Seoul Metropolitan Government, Seoul National University Boramae Medical Center, 39 Boramae-Gil, Dongjak-Gu, Seoul, Republic of Korea 156-707.
Official's Role
Study Director
12. IPD Sharing Statement
Citations:
PubMed Identifier
21396214
Citation
Park JS, Lee CH, Yim JJ, Yang SC, Yoo CG, Chung HS, Kim YW, Han SK, Shim YS, Kim DK. Impact of antibiotic prophylaxis on postbronchoscopy fever: a randomised controlled study. Int J Tuberc Lung Dis. 2011 Apr;15(4):528-35. doi: 10.5588/ijtld.10.0386.
Results Reference
derived
Learn more about this trial
The Impact of Antibiotic Prophylaxis on Incidence of Post-bronchoscopy Fever and Change of Serum Cytokines
We'll reach out to this number within 24 hrs